Shares for Ozempic parent company, Novo Nordisk, rise 42% in 2023

<img width="250" height="167" src="https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-250×167.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" decoding="async" style="float: left; margin-right: 5px;" link_thumbnail="" srcset="https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-250×167.jpg 250w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-700×466.jpg 700w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-768×512.jpg 768w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-120×80.jpg 120w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-245×163.jpg 245w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-500×333.jpg 500w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819.jpg 1255w" sizes="(max-width: 250px) 100vw, 250px" /><p>On Sunday, 17^th December, industry experts noted that while the firm has grown rapidly in 2023, keeping momentum throughout 2024 will be noticeably harder, with investors predicting only a 9% upside on average for next year.</p>
<div><img aria-describedby="caption-attachment-451569" decoding="async" class="wp-image-451569" src="https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891-700×700.jpg" alt="" width="98" height="98" srcset="https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891-700×700.jpg 700w, https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891-250×250.jpg 250w, https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891-150×150.jpg 150w, https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891-768×768.jpg 768w, https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891-120×120.jpg 120w, https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891-245×245.jpg 245w, https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891-500×500.jpg 500w, https://www.leaprate.com/wp-content/uploads/2023/12/FIN-LP-Shares-for-Ozempic-parent-company-rise-42-in-2023-5701933891.jpg 800w" sizes="(max-width: 98px) 100vw, 98px" /><p>Nick Cameron Source: LinkedIn</p></div>
<p>Portfolio manager at Antipodes Partners, Nick Cameron, noted 2024 investor predictions:</p>
<blockquote><p>[Novo is] an excellent R&amp;D company, and they’re very well managed. We can’t make the valuation work at these levels.</p></blockquote>
<p>Ailsa Craig, co-manager of the International Biotechnology Trust, also suggested that many investors are unsure whether “Lilly and Novo have run their course”. Craig continued:</p>
<blockquote><p>Have the huge sales numbers been factored into their valuations now, and is it sort of a bubble? That’s a big debate.</p></blockquote>
<hr />
<p><a href="https://finaffiliates.us20.list-manage.com/subscribe/post?u=e0dd4d77c259eb270712a4eeb&amp;id=fd200b8f75&amp;v_id=4291&amp;f_id=00946ce6f0" target="_blank" rel="noopener">Don’t miss out on the latest news, subscribe to LeapRate’s newsletter</a></p>
<hr />
<p><a href="https://www.leaprate.com/news/novo-nordisk-shares-riding-high-on-success-of-wegovy/" target="_blank" rel="noopener">Novo&#8217;s</a> upcoming obesity medication, CagriSema, is currently in advanced clinical trials and is said to help patients shed approximately 25% of their body weight. The company has admitted to being on the hunt for contracts surrounding CargiSema to ensure its 2024 results live up to this year’s standards. Ozempic’s GLP-1 drug also helps to treat mild dementia symptoms associated with Alzheimer’s disease.</p>
<p>The post <a rel="nofollow" href="https://www.leaprate.com/forex/technology/shares-for-ozempic-parent-company-novo-nordisk-rise-42-in-2023/">Shares for Ozempic parent company, Novo Nordisk, rise 42% in 2023</a> appeared first on <a rel="nofollow" href="https://www.leaprate.com">LeapRate</a>.</p>